Published in Gene Therapy Weekly, June 27th, 2002
"Compared with conventional methods, our product saves up to 70% of time required for such an optimization process", explained Wolfgang Kintzel, vice president Marketing at amaxa. "With our new optimization kit we are now able to address another key segment in the gene transfer market."
By launching the new kit for hard-to-transfect cell lines amaxa closes the gap between standard cell lines and primary cells. The Nucleofector technology can now be used for the complete...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.